Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial

Conclusions Compared with active conventional therapy, clinical remission rates were superior for abatacept and certolizumab pegol, but not for tocilizumab. Radiographic progression was low and similar between treatments. Trial registration number NCT01491815.
Source: Annals of the Rheumatic Diseases - Category: Rheumatology Authors: Tags: Editor's choice, ARD, Rheumatoid arthritis Source Type: research